Education
About Us
Working with TipRanks
Follow Us
Summit Therapeutics (SMMT)
NASDAQ:SMMT
SMMT Analyst Ratings
Strong Buy
10 Buy
1 Hold
1 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
SMMT Stock 12 Month Forecast
Average Price Target
$31.67
▲(32.84% Upside)
| Highest Price Target$50.00 | Average Price Target$31.67 | Lowest Price Target$12.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
H.C. Wainwright
$50
Buy
109.73%
Upside
Reiterated
09/02/25
Summit Therapeutics' Promising Developments with Ivonescimab Justify Buy Rating and $50 Price TargetValuation and Risks. Using an 8% discount rate and 4% terminal growth rate, our discounted cash flow (DCF)-based analysis results in an estimated EV of ~$43B, resulting in a price objective of $50 per share. We believe this discount rate is appropriate given the clinical data for ivonescimab as well as the extensive validation of PD-1 as a target via Keytruda's 40 prior regulatory approvals. Similarly, we believe that our 4% terminal growth rate appropriately factors in the myriad shots on goal from the large array of potential future indications. We do not include any of these non-core indications in our current valuation.
Wells Fargo
$30
Buy
25.84%
Upside
Reiterated
08/28/25
TD Cowen
―
Buy
―
Reiterated
08/26/25
UBS
$30
Buy
25.84%
Upside
Reiterated
08/22/25
Piper Sandler
$21
Hold
-11.91%
Downside
Initiated
08/19/25
Citizens JMP
$40
Buy
67.79%
Upside
Reiterated
08/19/25
Clear Street
$30→$33
Buy
38.42%
Upside
Reiterated
08/13/25
Truist Financial
―
Buy
―
Reiterated
08/13/25
Evercore ISI
$30→$34
Buy
42.62%
Upside
Reiterated
08/12/25
Citi
$35
Buy
46.81%
Upside
Assigned
08/12/25
Leerink Partners
$12
Sell
-49.66%
Downside
Reiterated
08/12/25
We continue to believe it is critical that Summit (SMMT, UP) secure a partnership that will support VEGFA/ PD-1 ivonescimab's (ivo) global development. The company's upsized $360 M ATM offering initiated on August 11 could provide the company with temporary alleviation of their cash overhang, but it does not preclude the need to partner ivo. Other than their collaboration with RVMD (OP, Chang), Summit lacks the means to rapidly advance ivo in combination regimens. The question for us, however, is which PharmaCo, with an internal oncology portfolio of combinable assets, is open to deal economics that would return value to SMMT shareholders at its current valuation (EV $23 B as of the close on August 11) —upfront that exceeds $7.7 B (see HERE for our calculation at the time of the AZN (OP, Berens) partnership buzz in early July).
Cantor Fitzgerald
―
Buy
―
Reiterated
07/28/25
Jefferies
$44
Buy
84.56%
Upside
Reiterated
05/31/25
Stifel Nicolaus
$40
Buy
67.79%
Upside
Reiterated
03/11/25
Goldman Sachs
$42
Buy
76.17%
Upside
Initiated
02/28/25
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
H.C. Wainwright
$50
Buy
109.73%
Upside
Reiterated
09/02/25
Summit Therapeutics' Promising Developments with Ivonescimab Justify Buy Rating and $50 Price TargetValuation and Risks. Using an 8% discount rate and 4% terminal growth rate, our discounted cash flow (DCF)-based analysis results in an estimated EV of ~$43B, resulting in a price objective of $50 per share. We believe this discount rate is appropriate given the clinical data for ivonescimab as well as the extensive validation of PD-1 as a target via Keytruda's 40 prior regulatory approvals. Similarly, we believe that our 4% terminal growth rate appropriately factors in the myriad shots on goal from the large array of potential future indications. We do not include any of these non-core indications in our current valuation.
Wells Fargo
$30
Buy
25.84%
Upside
Reiterated
08/28/25
TD Cowen
―
Buy
―
Reiterated
08/26/25
UBS
$30
Buy
25.84%
Upside
Reiterated
08/22/25
Piper Sandler
$21
Hold
-11.91%
Downside
Initiated
08/19/25
Citizens JMP
$40
Buy
67.79%
Upside
Reiterated
08/19/25
Clear Street
$30→$33
Buy
38.42%
Upside
Reiterated
08/13/25
Truist Financial
―
Buy
―
Reiterated
08/13/25
Evercore ISI
$30→$34
Buy
42.62%
Upside
Reiterated
08/12/25
Citi
$35
Buy
46.81%
Upside
Assigned
08/12/25
Leerink Partners
$12
Sell
-49.66%
Downside
Reiterated
08/12/25
We continue to believe it is critical that Summit (SMMT, UP) secure a partnership that will support VEGFA/ PD-1 ivonescimab's (ivo) global development. The company's upsized $360 M ATM offering initiated on August 11 could provide the company with temporary alleviation of their cash overhang, but it does not preclude the need to partner ivo. Other than their collaboration with RVMD (OP, Chang), Summit lacks the means to rapidly advance ivo in combination regimens. The question for us, however, is which PharmaCo, with an internal oncology portfolio of combinable assets, is open to deal economics that would return value to SMMT shareholders at its current valuation (EV $23 B as of the close on August 11) —upfront that exceeds $7.7 B (see HERE for our calculation at the time of the AZN (OP, Berens) partnership buzz in early July).
Cantor Fitzgerald
―
Buy
―
Reiterated
07/28/25
Jefferies
$44
Buy
84.56%
Upside
Reiterated
05/31/25
Stifel Nicolaus
$40
Buy
67.79%
Upside
Reiterated
03/11/25
Goldman Sachs
$42
Buy
76.17%
Upside
Initiated
02/28/25
Best Analysts Covering Summit Therapeutics
1 Month
xxx
Success Rate
6/8 ratings generated profit
Average Return
+13.74%
assigned a xxx
rating 23 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 75.00% of your transactions generating a profit, with an average return of +13.74% per trade.
3 Months
xxx
Success Rate
6/6 ratings generated profit
Average Return
+22.63%
reiterated a xxx
rating 3 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 100.00% of your transactions generating a profit, with an average return of +22.63% per trade.
1 Year
Success Rate
7/7 ratings generated profit
Average Return
+243.83%
reiterated a buy rating 6 months ago
Copying Bradley Canino's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +243.83% per trade.
2 Years
xxx
Success Rate
7/7 ratings generated profit
Average Return
+251.96%
reiterated a xxx
rating 6 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +251.96% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
SMMT Analyst Recommendation Trends
Rating
May 25
Jun 25
Jul 25
Aug 25
Sep 25
Strong Buy
11
12
11
11
6
Buy
19
23
14
17
11
Hold
10
6
1
1
1
Sell
0
2
3
3
1
Strong Sell
0
0
0
1
1
total
40
43
29
33
20
Each month's total comprises the sum of three months' worth of ratings.
SMMT Financial Forecast
SMMT Stock Forecast FAQ
What is SMMT’s average 12-month price target, according to analysts?
Based on analyst ratings, Summit Therapeutics’s 12-month average price target is 31.67.
What is SMMT’s upside potential, based on the analysts’ average price target?
Summit Therapeutics has 32.84% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is SMMT a Buy, Sell or Hold?
Summit Therapeutics has a consensus rating of Strong Buy which is based on 10 buy ratings, 1 hold ratings and 1 sell ratings.
What is Summit Therapeutics’s price target?
The average price target for Summit Therapeutics is 31.67. This is based on 12 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $50.00 ,the lowest forecast is $12.00. The average price target represents 32.84% Increase from the current price of $23.84.
The highest analyst price target is $50.00 ,the lowest forecast is $12.00. The average price target represents 32.84% Increase from the current price of $23.84.
What do analysts say about Summit Therapeutics?
Summit Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 12 Wall Streets Analysts.
How can I buy shares of SMMT?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.